Eagle's Eye View: Your Weekly CV Update From ACC.org: Recent Episodes
American College of Cardiology
The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
In this week's View, Dr. Eagle looks at a collaborative analysis of three randomized trials that investigated inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy. He then covers the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. Finally, Dr. Eagle explores ACTIVE-AF, a randomized controlled trial on exercise and physical activity program in patients with atrial fibrillation.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the value of the balloon pulmonary angioplasty procedure for patients with chronic thromboembolic pulmonary hypertension. He then reviews the sub analysis of the HOST EXAM trial assessing the benefit of aspirin versus clopidogrel as a maintenance strategy after coronary stenting.
Finally, Dr. Eagle explores the BIOVASC trial weighing in on immediate versus staged complete revascularization in patients presenting with acute coronary syndrome and multivessel coronary disease.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Deepak Bhatt sits in for Dr. Eagle and discusses heart failure following anti-inflammatory medications in patients with type 2 diabetes mellitus, then looks at the results of the ARCHITECT Study concerning alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia.
Finally, Dr. Bhatt explores a state-of-the-art review of the benefits of exercise in cardiovascular diseases, from mechanisms to clinical implementation.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Deepak Bhatt discusses a three-decade exploration from the Aortic Institute at Yale University on the rate of the unoperated ascending thoracic aortic aneurysm. He then looks at the final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Finally, Dr. Bhatt explores subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses implantable defibrillator system shock function, mortality, and cause of death after magnetic resonance imaging. He then explores the association of preoperative medical consultation with a reduction in adverse postoperative outcomes and use of processes of care.
Finally, Dr. Eagle explores a comprehensive analysis of a multicenter registry that examined the prognostic implications of discordant low-gradient severe aortic stenosis.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the incidence of cardiac arrest during sports among women versus men, then looks at a scientific statement from the American Heart Association on atrial fibrillation occurring during acute hospitalization. Finally, Dr. Eagle explores the results reported in the RACING Trial that addressed the use of moderate-intensity statins with ezetimibe vs. high-intensity statins in patients with diabetes and atherosclerotic cardiovascular disease.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses a prespecified analysis of the NUDGE-FLU trial that reported on the effectiveness of electronic nudges on influenza vaccination rate in older adults with cardiovascular disease, then looks at a comparison of the ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Finally, Dr. Eagle explores a long-term study of pregnancy complications and long-term mortality in a diverse cohort.
Subscribe to Eagle’s Eye View
Dr. Deepak Bhatt reviews the Day 3 late-breaking science from ACC.23, including FREEDOM COVID ANTICOAG (0:52), STELLAR Phase III (1:49), and PULSED AF (2:49). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation.
Subscribe to Eagle’s Eye View
Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from ACC.23, including BIOVASC (0:39), UK MINI MITRAL (2:12), and BETTER CARE HF (4:15). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation.
Subscribe to Eagle’s Eye View
Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from ACC.23, including CLEAR OUTCOMES (0:41), TRILUMINATE (2:35) and STOP CA (5:25).
The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using #ACC23 to join the conversation.
In this week’s View, Dr. Eagle discusses Lp(a) as a main driver for the risk of ASCVD, MI, and aortic valve stenosis independent of CRP. This article is timely as we continue to attempt to lower the risks with ongoing trials currently working on relevant therapeutic options for lowering Lp(a).
Then Dr. Eagle looks at women with CHD and mild PH who appear to have better pregnancy outcomes as compared with those with moderate-to-severe PH.
Finally, Dr. Eagle explores the PARTNER Trials and its insights concerning cardiac damage and quality of life after Aortic Valve Replacement.
We are looking forward to continuing to engage you during ACC.23 (March 4-6) in this formidable time of education! Check back for further updates!
Subscribe to Eagle’s Eye View
Cardiovascular professionals are coming together for ACC.23 in New Orleans, March 4-6, to learn the latest practice-changing breakthrough research and trials results from around the world. In this View episode, guest host Deepak Bhatt MD, MPH, FACC, offers a preview of some of the hottest trials at ACC.23.
Kicking us off on Day 1, Saturday, March 4, we will hear the positive outcomes from the CLEAR OUTCOMES trial and the favorable data for structural heart disease coming out of the TRILUMINATE trial.
Day 2, Sunday, March 5, can’t be missed! Among the many presentations: UK MINI MITRAL weighs the minimally invasive approach versus conventional sternotomy for mitral valve repair surgery and the RENOVATE COMPLEX PCI trial that examines intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention – a subject of particular interest to interventionalists. And that’s just the beginning: the 5-year final results from the COAPT trial are in; the 3-year outcomes from the EVOLUT low risk trial sound positive and continue to be in favor of TAVR; the BIOVASC trial data will be released, and it’s likely the findings will continue to be in favor of complete revascularization strategies in patients presenting with acute coronary syndromes and multivessel coronary disease.
On Monday, the last day of the conference, Dr. Valentin Fuster will present the FREEDOM COVID ANTICOAG trial, discussing anticoagulation strategies in non-critically ill hospitalized COVID patients. Next up, the STELLAR trial, a study of sotatercept in combination with background therapy for the treatment of pulmonary arterial hypertension, will be presented. And finally, the findings of the collaborative analysis of participants in the three major trials are also scheduled: the PROMINENT, REDUCE-IT, STRENGTH trials.
Be sure to check back on Eagle's Eye View throughout the meeting for further updates.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses a clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions on renal denervation in the management of hypertension in adults, then looks at the risk of surgical mitral valve repair for primary mitral regurgitation. Finally, Dr. Eagle explores an observational study that examines primary prevention of acute cardiovascular events by influenza vaccination.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the recent expert panel statement on positron emission tomography (PET) for assessment of coronary microvascular dysfunction, then looks at the impact of transcatheter mitral valve repair availability on the volume and outcomes of surgical repair. Finally, Dr. Eagle explores the 2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions, then looks at practical approaches to genetic screening in cardiomyopathies. Finally, Dr. Eagle explores long-term outcomes of perioperative myocardial infarction or injury after non-cardiac surgery.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the ACC Expert Consensus Documents on comprehensive multidisciplinary care for the patient with cardiac amyloidosis, then looks at findings from the SPRINT Trial on the effect of intensive blood pressure control on troponin and natriuretic peptide levels. Finally, Dr. Eagle explores early extracorporeal CPR for refractory out-of-hospital cardiac arrest compared to traditional CPR.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses recurrent venous thromboembolism and bleeding with extended anticoagulation and the VTE-PREDICT risk score, then looks at infective endocarditis after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores aspirin and low-molecular-weight heparin for thromboprophylaxis after a fracture.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the treatment of radiation-induced aortic stenosis, then looks at PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. Finally, Dr. Eagle explores myocardial injury on CMR in patients with COVID-19 and suspected cardiac involvement.
Subscribe to Eagle’s Eye View
https://twitter.com/keaglemd
https://twitter.com/accintouch?lang=en
In this week’s View, Dr. Eagle discuses heart failure drug treatment - inertia, titration and discontinuation as analyzed in EVOLUTION HF, a multinational observational study, then looks at Non-Obstructive Coronary Arteries (INOCA), and insights gained from the ISCHEMIA Trial. Finally, Dr. Eagle explores findings regarding exercise volume versus intensity and the progression of coronary atherosclerosis in middle-aged and older athletes from the MARC-2 Study.
Subscribe to Eagle’s Eye View
Top Clinical Trials
It was another great year for trial coverage on ACC.org! There were almost 140,000 unique views of the top 10 trials and top 10 trial updates for the year. Treatment of heart failure and of hypertrophic cardiomyopathy were hot topics. In addition to covering new trials, we updated prior trials with any related significant presentations or publications. We have added new features for our learners to make clear what is updated compared with the prior version of a clinical trial summary. Hopefully, this change allows quicker reading of these trial synopses. Interestingly, some of the trial updates had more views than de novo trial coverage. We have also started providing visual abstracts for some of the key trials at the major meetings. We are striving to make ACC.org a very user-friendly educational portal. On behalf of the ACC.org staff, Happy Holidays and a joyous New Year to you all!
Deepak L. Bhatt, MD, MPH, FACC Senior Associate Editor, Clinical Trials and News, ACC.org
Subscribe to Eagle’s Eye View
In 2022 with much of the care landscape returning to more normalcy after the COVID-19 pandemic eased, we saw the most visited journal scan content on ACC.org once again focused on common areas of cardiovascular practice and areas with advances in therapy. ACC.org is a home for condensed, digestible content particularly around important summary documents like the guidelines and consensus statements. In 2022, we saw release of new heart failure guidelines, new guidelines for the evaluation of cardiovascular disorders prior to non-cardiac surgery and also for pulmonary hypertension, a summary statement on the use of aspirin for primary prevention, and a state-of-the-art summary on rhythm control for atrial fibrillation.
The ACC looks forward to an exciting 2023 and the opportunity to continue to partner with you in the provision of “state of the art” information for your practice!
— Kim A. Eagle, MD, MACC
Subscribe to Eagle’s Eye View
In this interview, Dhanunjaya "DJ" Lakkireddy MBBS, FACC and Alison L. Bailey MD FACC discuss the Top Takeaways from 2022: Electrophysiology.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this week’s View, Dr. Eagle discusses a systematic review and meta-analysis of aortic stenosis progression, then looks at a meta-analysis of randomized trials on the use of dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk. Finally, Dr. Eagle explores the three-year results of the SUCCOUR trial that investigated cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy'
Subscribe to Eagle’s Eye View
Join Akl Fahed MD, MHP, FACC and Dianna Milewicz MD, PhD as they discuss using genetic testing to inform treatment planning and care management of patients with aortopathies .
Subscribe on iTunes | Subscribe on Google Play |
In this week’s View, Dr. Eagle discusses medical masks versus N95 respirators for preventing COVID-19 among health care workers, then looks at an excellent metanalysis of antioxidant micronutrient supplementation to reduce cardiovascular risk. Finally, Dr. Eagle explores the prognosis of myocarditis developing after mRNA COVID-19 vaccination compared to viral myocarditis.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses trends in the use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, then looks at a collaborative meta-analysis of large placebo-controlled trials that examines the impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes. Finally, Dr. Eagle explores insights from the PEGASUS-TIMI 54 trial regarding patient selection for long-term secondary prevention with ticagrelor.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discuses hypertension management in patients with cardiovascular comorbidities, then looks at a patient-level analysis of Phase III trials that examines Inclisiran and cardiovascular events. Finally, Dr. Eagle explores the STROKESTOP study on the cost-effectiveness of population screening for atrial fibrillation.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the most important aspects of the new ACC AHA Guidelines for the diagnosis and management of aortic disease.
Subscribe to Eagle’s Eye View
Drs. Deepak Bhatt, Kim Eagle and Payal Kohli review Day 3 late-breaking science from AHA 2022, including ENHANCE-AF (0:32), PRECSION (2:40), BrightHTN (4:08), and SPYRAL HTN-ON (6:41). The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.
Drs. Deepak Bhatt, Kim Eagle and Payal Kohli review Day 2 late-breaking science from AHA 2022, including ECMO-CS (0:42), RESPECT-EPA (2:22), ISCHEMIA-EXTENDed (5:45) and EMPA-KIDNEY (7:39). The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.
In this special AHA episode of Eagle’s Eye View, Drs. Deepak Bhatt, Kim Eagle and Payal Kohli discuss highlights from Day 1 of the AHA 2022 late-breaking science, including TRANSFORM-HF, DCP, PROMINENT, and IRONMAN. The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.
In this week’s View, Dr. Eagle discusses a secondary analysis of the REPRISE III randomized clinical trial on long-term outcomes of transcatheter aortic valve replacement with the Lotus valve vs the CoreValve/EvolutR, then looks at iron deficiency and cardiovascular disease. Finally, Dr. Eagle explores the association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation.
Subscribe to Eagle’s Eye View
In this episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the most important and clinically transformative studies being presented at the AHA 2022 Conference, November 5-7.
Day One includes two major studies on diuretics: primary results from the TRANSFORM HF Trial, examining the comparative effectiveness of torsemide versus furosemide in heart failure, and from the DCP Trial on chlorthalidone compared to hydrochlorothiazide for the prevention of cardiovascular events in patients with hypertension. Day One also includes a presentation on PROMINENT, a randomized trial of pemafibrate for triglyceride reduction in the prevention of cardiovascular disease.
Day Two includes a major and important presentation of data from EMPA-KIDNEY, examining empagliflozin and cardiovascular outcomes in patients with chronic kidney disease. QUARTET USA, a randomized control trial investigating the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension is also on the agenda. The primary results of ECMO-CS, a multicenter randomized trial on extracorporeal membrane oxygenation in the therapy of cardiogenic shock will be presented as well.
The third and final day opens with BEST-CLI Trial, looking at the best endovascular versus best surgical therapy for patients with chronic limb-threatening ischemia, followed by a primary analysis from the RAPID Trial, focusing on self-administered etripamil for termination of spontaneous paroxysmal supraventricular tachycardia, followed by results from the Phase 2 NOVA Trial, examining the efficacy and safety of botulinum toxin type A for the prevention of postoperative atrial fibrillation in cardiac surgery patients. There will also be a group of presentations on the treatment of persistent hypertension, beginning with the top-line results from FRESH, looking at the first-in-class aminopeptidase-A inhibitor firibastat in treatment-resistant hypertension, followed by data from, PRECISION, a randomized controlled study including a withdrawal phase, investigating the sustained blood pressure-lowering effect with the dual endothelin receptor antagonist aprocitentan in resistant hypertension, followed in turn by the results from BrightHTN, a Phase 2 randomized double-blind placebo-controlled trial evaluating the efficacy and safety of baxdrostat in patients with treatment-resistant hypertension, and concluding with information on the 6-month primary results of SPYRAL HTN-ON, investigating the effect of radiofrequency renal denervation on blood pressure in the presence of antihypertensive drugs.
AHA 2022 promises to be a rich and rewarding experience for those who can attend in person or participate virtually.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the European Atherosclerosis Society’s consensus statement on lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, then looks at CHD screening in kidney and liver transplant candidates.
In this week’s View, Dr. Eagle discusses the TIME Study, a prospective, randomized, open-labe,l blinded-endpoint clinical trial exploring cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives, then looks at phenotyping the hypertensive heart. Finally, Dr. Eagle takes a look at a multinational study on programmed ventricular stimulation as an additional primary prevention risk stratification tool in arrhythmogenic right ventricular cardiomyopathy.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Deepak Bhatt sits in for Dr. Eagle to discuss TIMING, a registry-based randomized controlled noninferiority study that examines early versus delayed non–Vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation, then looks at the Fingersture study on plaque histology and myocardial disease in sudden coronary death. Finally, Dr. Bhatt takes a look at a recent paper on evolving management concepts for left main coronary disease.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses the Fitbit Heart Study that examines the detection of atrial fibrillation in a large population using wearable devices, then looks at the long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention. Finally, Dr. Eagle discusses risk assessment of hypertensive events during pregnancy.
Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle discusses a scientific statement from the American Heart Association on the management of patients at risk for and with left ventricular thrombus, then looks at the nationwide CONCEPTION study concerning pregnancy and the onset of chronic hypertension. Finally, Dr. Eagle examines the risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years of age in France.
Subscribe to Eagle’s Eye View
In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 3 of the TCT 2022 late-breaking science, including PCSK9 Inhibition, FAVOR III China, and SCAAR. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC’s Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.
In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 2 of the TCT 2022 late-breaking science, including RADIANCE II, SYMPLICTY HTN-3, pulmonary denervation, and UNIVERSAL. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC’s Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.
In this special ESC Congress episode of Eagle’s Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 1 of the TCT 2022 late-breaking science, including PROTECTED TAVR, Amulet IDE, and CLASP IID. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC’s Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.
In this week’s View, Dr. Eagle discusses a multinational analysis with external cohort validation of sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland:, then looks at a comprehensive meta-analysis of five randomized controlled trials concerning SGLT-2 inhibitors in patients with heart failure. Finally, Dr. Eagle examines routine functional testing or standard care in high-risk patients after PCI.
In this episode, guest host Dr. Deepak Bhatt offers a preview of some of the most important and clinically transformative studies being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference taking place Sept. 16-19 in Boston, MA. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC’s Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022to join the conversation.
In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss a prespecified analysis of the DELIVER Trial that investigated the efficacy and safety of dapagliflozin according to frailty in patients with heart failure, then looks at a separate paper on the DELIVER Trial that examines dapagliflozin for heart failure according to body mass index. Finally, Dr. Bhatt examines a prospective cohort study of UK Biobank participants that looked at the association between device-measured physical activity and incident heart failure.
In this special ESC Congress episode of Eagle’s Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 4 of the ESC Congress 2022: late-breaking science and featured clinical research, including POISE-3, SPYRAL HTN-ON MED, EMPULSE, and FIDELITY.
In this special ESC Congress episode of Eagle’s Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 3 of the ESC Congress 2022: late-breaking science and featured clinical research, including INVICTUS, FACTOR XIa trials, AXIOMATIC-SSP, MOMENTUM 3, and POST-PCI.
In this special ESC Congress episode of Eagle’s Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 2 of the ESC Congress 2022: late-breaking science and featured clinical research, including DANCAVAS, REVIVED-BCIS2, ADVOR, ALL-HEART, and DELIVER.
In this special ESC Congress episode of Eagle’s Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 1 of the ESC Congress 2022: late-breaking science and featured clinical research, including SECURE, ENTRIGUE, TIME, and REDUCE-IT.
In this week’s View, Dr. Eagle discusses the comparative risks of initial aortic events associated with genetic thoracic aortic disease, then looks at the harmonization of the American College of Cardiology/American Heart Association’s and the European Society of Cardiology/European Society of Hypertension’s Guidelines on blood pressure and hypertension. Finally, Dr. Eagle examines a study looking at how polygenic risk score may predict sudden death in patients with coronary disease and preserved systolic function.
In this episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the most important and clinically transformative studies being presented at the ESC 2022 Conference, August 26-29.
Day One includes: more data from the EMPEROR trial on the mechanisms and clinical benefits of SGLT2i in heart failure, the TAILOR-PCI randomized trial on genotype-guided oral P2Y12 inhibitor therapy, phase 2 data from the ENTRIGUE study on pegozafermin for the treatment of severe hypertriglyceridemia, and the results of the TIME trial on the timing of morning versus evening medication. Also on Day One, Dr. Valentine Fuster will present the results of the SECURE trial, a polypill strategy in secondary prevention. There will also be a presentation of the ASCEND study on the effects of aspirin and omega−3 fatty acid supplements on heart failure. Dr. Bhatt will present data from the REDUCE-IT trial on the significant reduction in ST-Elevation MI with icosapent ethyl. Day One will also cover the EXHAUSTION project, investigating air temperature and cardiovascular disease, as well as the ADDICT-ICCU study on carbon monoxide and acute cardiac events.
Day Two will include: a presentation by Davada Perera on REVIVED, investigating percutaneous revascularization for ischemic ventricular dysfunction, ALL-HEART data on allopurinol and cardiovascular outcomes in ischemic heart disease, and a major presentation by Scott Solomon on the DELIVER trial, examining dapagliflozin in heart failure with mildly reduced and preserved ejection fraction. There will also be a number of pooled analyses on Day Two, including one looking at DAPA-HF and DELIVER, and a pre-specified meta-analysis of DELIVER and EMPEROR-Preserved. Together these studies will firmly cement the concept of the SGLT-2 inhibitors class as a heart failure medication.
Day Three opens with an important presentation on INVICTUS, exploring rivaroxaban versus VKA for rheumatic atrial fibrillation. There will also be a group of presentations on some modest but significant Phase 2 trials on factor XIa inhibitor asundexian. Additionally, Renalto Lopes will present data on the APOLLO trial exploring apixaban for prophylaxis of thromboembolic outcomes in COVID-19, and the five-year data from the MOMENTUM 3 study on LVAD Therapy will be presented.
On the fourth and final day, presentations include the clinical outcomes at 5 years of follow-up in the ISCHEMIA-CKD EXTEND trial, the review of the MASTERDAPT trial data at 15 months, the primary results of FOURIER-OLE, and data from the PANTHER Trial on P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.
ESC 2022 promises to be a rich and rewarding experience for those who can attend in person or participate virtually.
In this week’s View, Dr. Eagle discusses the impact of medication non-adherence in a clinical trial of dual antiplatelet therapy, then looks at sex difference in outcomes following transcatheter aortic valve replacement in bicuspid aortic stenosis. Finally, Dr. Eagle comments on a recent observational cohort study that explores the persistence of somatic symptoms after COVID.
In this week’s View, Dr. Eagle discusses a scientific statement from the American Heart Association on the medical insights and clinical implications of sleep-disordered breathing and cardiac arrhythmias in adults, then looks at the prevalence and prognosis of discordant grading and flow-gradient patterns in patients with moderate aortic stenosis. Finally, Dr. Eagle explores JACC’s recently published paper on what clinicians need to know concerning the ongoing dobutamine shortage.
In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss the associations of atrial fibrillation after noncardiac surgery with stroke, subsequent arrhythmia, and death, then looks at how lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Finally, Dr. Bhatt explores JACC’s State-of-the-Art Review of cardiovascular imaging for ischemic heart disease in women, and the need for a paradigm shift.
In this week’s View, Dr. Eagle discusses the JACC State of the Art Review of the definitions, outcomes, and evidence gaps surrounding aortic valve hemodynamics, then looks at cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium–glucose cotransporter-2 inhibitors versus metformin. Finally, Dr. Eagle explores the incidence, associated risk factors, and outcomes of postoperative arrhythmia after upper gastrointestinal surgery.
In this week’s View, Dr. Eagle discusses the association of blood viscosity with mortality among patients hospitalized with COVID-19, then looks at a systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Finally, Dr. Eagle summarizes an open-label, blinded-outcome, randomized non-inferiority trial that examined thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke.
In this week’s View, Dr. Eagle discusses aneurysm growth, survival, and quality of life in untreated thoracic aortic aneurysms, then looks at the criteria for defining stages of cardiogenic shock severity and how that affects prognosis. Finally, Dr. Eagle explores the risk and timing of noncardiac surgery after transcatheter aortic valve implantation.
In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss the effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF), then looks at the SynABPM 1 study that explores the association between hypotension during 2-hour ambulatory blood pressure monitoring and reflex syncope. Finally, Dr. Bhatt examines a report on the first commercial use in a multicenter experience of the PASCAL system, a transcatheter leaflet repair system for symptomatic tricuspid regurgitation.
In this week’s View, Dr. Eagle discusses the newly published table that lists drug-drug interactions with the anti-viral agent Paxlovid, used in treating COVID-19, then looks at an analysis of the LIFE Trial Run-In that examines the tolerability of sacubitril/valsartan in patients with advanced heart failure. Finally, Dr. Eagle explores the CABANA randomized clinical trial and its insights into the cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation.
In this week’s View, Dr. Eagle discusses rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease, then looks at pre-operative atrial fibrillation and cardiovascular outcomes after non-cardiac surgery. Finally, Dr. Eagle explores a cohort study of claims databases that analyzes the risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.
In this week’s View, Dr. Eagle discusses a prospective evaluation of cardiovascular risk ten years after a hypertensive disorder of pregnancy, then looks at the effect of varenicline added to counseling on smoking cessation among African American daily smokers. Finally, Dr. Eagle explores Dr. Nanette Wenger’s Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care in a Presidential Advisory from the American Heart Association.
In this week’s View, Dr. Eagle discusses the association of sugar-sweetened, artificially sweetened, and unsweetened coffee consumption with all-cause and cause-specific mortality, then looks at the association of sedentary time and physical activity with the risk of stroke among US adults. Finally, Dr. Eagle explores the prospective evaluation of autonomic dysfunction in post-acute sequela of COVID-19.
In this week’s View, Dr. Eagle discusses nighttime masked uncontrolled hypertension among patients with chronic kidney disease, then looks at the characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Finally, Dr. Eagle explores the incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention.
In this week’s View, Dr. Eagle discusses cardiovascular outcomes in aortopathy in the GenTAC Registry of Genetically Triggered Aortic Aneurysms and Related Conditions, then looks at a systematic review and updated meta-analysis of the associations of dietary cholesterol, serum cholesterol, and egg consumption with overall and cause-specific mortality. Finally, Dr. Eagle explores the risk for acute myocardial infarction after ophthalmologic procedures.
In this week’s View, Dr. Eagle discusses the effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis, then looks at a multicenter evaluation of the rapid exclusion of acute myocardial injury and infarction with a single high-sensitivity cardiac troponin T in the emergency department. Finally, Dr. Eagle explores a meta-analysis of randomized controlled trials on the timing of invasive strategy in non-ST-elevation acute coronary syndrome.
In this week’s View, Dr. Eagle discusses current recommendations and uncertainties for surgical treatment of infective endocarditis in a comparison of American and European cardiovascular guidelines, then looks at a recent JACC State-of-the-Art Review on the increasing role of rhythm control in patients with atrial fibrillation. Finally, Dr. Eagle explores the association of influenza vaccination with cardiovascular risk.
In this week’s View, Dr. Eagle discusses insights from the DAPA-HF Trial concerning the initial decline in Estimated Glomerular Filtration Rate following the initiation of dapagliflozin in patients with heart failure and reduced ejection fraction, then looks at which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation. Finally, Dr. Eagle explores the use of high-intensity statin use among patients with atherosclerosis in the U.S.
In this week’s View, Dr. Eagle discusses automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest, then looks at the USPSTF report on aspirin for primary prevention. Finally, Dr. Eagle explores the association of race, ethnicity, and rurality with major leg amputation or death among Medicare beneficiaries hospitalized with diabetic foot ulcers.
In this week’s View, Dr. Eagle discusses SARS-CoV-2 Infection and associated cardiovascular manifestations and complications in children and young adults, then looks at a recent paper in Circulation on the prevalence, characteristics, and outcomes of COVID-19–associated acute myocarditis. Finally, Dr. Eagle explores how Twitter promotion is associated with higher citation rates of cardiovascular articles.
: In this special ACC.22 episode of Eagle’s Eye View, Drs. Kim Eagle, Payal Kohli and Deepak Bhatt discuss highlights from Day 3 of the ACC.22 late-breaking science and featured clinical research, including POISE-3, SPYRAL HTN-ON MED, EMPULSE, and FIDELITY.
In this special ACC.22 episode of Eagle’s Eye View, Drs. Kim Eagle, Payal Kohli and Deepak Bhatt discuss highlights from Day 2 of the ACC.22 late-breaking science and featured clinical research, including PACMAN AMI, SuperWIN, DIAMOND, and IVVE.
In this special ACC.22 episode of Eagle’s Eye View, Drs. Kim Eagle, Payal Kohli and Deepak Bhatt discuss highlights from Day 1 of the ACC.22 late-breaking science and featured clinical research, including CHAP, SCORED, COMPLETE, and Bentracimab.
In this week’s View, Dr. Eagle discusses a new Expert Consensus Decision Pathway released by the ACC that addresses the evaluation and management of some of the more common cardiovascular sequelae in adults with COVID-19. The Pathway, published March 16 in the Journal of the American College of Cardiology, specifically addresses myocarditis and other types of myocardial involvement, patient-centered approaches for long COVID, and offers guidance on resumption of exercise following COVID-19.
In this View episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the hottest trials at the ACC 2022 Conference being held April 2-4. ACC 2022 promises to be a rich and rewarding experience, in person and virtually.
In this week’s View, Dr. Eagle discusses a comparison of patients infected with Delta versus Omicron COVID-19 variants, then looks at a post-hoc analysis of the EMPEROR-Preserved trial on mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction. Finally, Dr. Eagle explores a recent NCDR Registry paper on sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock.
In this week’s View, Dr. Eagle discusses the effect of Pelacarsen on lipoprotein(a) cholesterol and corrected low density lipoprotein cholesterol. He also explores a systematic review and meta-analysis of bariatric surgery and cardiovascular disease. And finally, Dr. Eagle highlights a recent sub-study on the comprehensive quality of life outcomes with Invasive versus conservative management of chronic coronary disease in the ISCHEMIA trial.
In this week’s View, Dr. Eagle discusses a JACC State-of-the-Art Review on left ventricular thrombus following acute myocardial infarction. He also highlights the PARTNER 3 Bicuspid Registry for transcatheter aortic valve replacement in low surgical risk patients. And finally, Dr. Eagle explores the JACC paper on restoring sinus rhythm to reverse cardiac remodeling and reduce valvular regurgitation in patients with atrial fibrillation.
In this week’s View, Dr. Eagle discusses sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension. He also examines anticoagulation in patients with COVID-19. Finally, Dr. Eagle explores JACC’s Review Topic of the Week: renal compression in heart failure – specifically, the Renal Tamponade Hypothesis.
In this week’s View, Dr. Eagle highlights a meta-analysis of statin intolerance. He also discusses the estimation of recurrent atherosclerotic cardiovascular event risk. And finally, Dr. Eagle reviews SARS-CoV-2 reinfection with and without mRNA vaccine.
In this week’s View, Dr. Eagle highlights a study comparing a proteomics-based risk model to a traditional risk factor model in predicting recurrent atherosclerotic events in two observational cohorts, He also discusses the prevalence of noncalcified and calcified plaque in symptomatic adults and its association with cardiovascular disease (CVD) events across the low-density lipoprotein cholesterol (LDL-C) spectrum. And finally, Dr. Eagle reviews the effects of empagliflozin on heart failure hospitalizations across the full range of left ventricular ejection fractions.
This week’s View examines the quality of evidence of the association of foods and nutrients with CV disease and diabetes; AHA’s Life’s Simple 7: lifetime risk of coronary heart disease by polygenic risk and lifestyle; and myocarditis after the COVID-19 vaccine.
This week’s View highlights a position paper on optimal follow-up after acute pulmonary embolism; antithrombotic therapy in patients who have AFib and have had either ACS or PCI; and the ESC Guidelines for prevention.
This week’s View examines biomarkers early in pregnancy and their ability to predict hypertension risk and other disorders; clinical outcomes and pre-hospital delay among patients presenting with non–ST-segment elevation myocardial infarction (NSTEMI); and important ‘key points to remember’ from a state-of-the-art review on the diagnosis and evaluation of hypertrophic cardiomyopathy (HCM).
This week’s View highlights the use of ICD therapy in ischemic vs. non-ischemic cardiomyopathy; what are the (FDG)-positron emission tomography (PET) and MRI findings, and abnormalities in patients with COVID-19; and a meta-analysis examining oral anticoagulation in AFib.
This week’s View discusses the one-year outcomes of blinded physiological assessment of residual ischemia after successful PCI (DEFINE PCI); delineating whether coronary artery spasm is epicardial, microvascular, or both; and the comparison of different strategies for identifying cardiac testing in patients with chest pain.
This week’s View looks at differences in results of the REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) and STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) trials and if they can be explained by the active and comparator oils on lipid traits and C-reactive protein (CRP). Dr. Eagle also examines whether traditional CV risk factors are associated with incident ASCVD among those with absent coronary calcium. And finally, Dr. Eagle looks at driving restrictions in those receiving a secondary prevention ICD.
This week’s View examines the clinical course and short-term outcomes of suspected myocarditis following COVID-19 vaccination in patients <21 years of age; the effect of empagliflozin in patients with heart failure across the spectrum of LVEF; and the safety and immunogenicity profiles of different COVID-19 vaccine booster regimens.
Subscribe to Eagle’s Eye View
This week’s View examines whether high-grade premature ventricular contractions (PVCs) during stress testing predict mortality in asymptomatic individuals; trends in transcatheter mitral valve therapies in the United States; and key perspectives on the newly released ACC/AHA/SCAI Coronary Revascularization Guideline.
Subscribe to Eagle’s Eye View
This episode of Eagle’s Eye View examines direct links between distinct components of physical activity, their changes over time, and cardiorespiratory fitness rate; the rate of recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation; and the effects of spinal vs. general anesthesia on the ability to walk in older adults undergoing hip surgery.
Subscribe to Eagle’s Eye View
This episode of Eagle’s Eye View examines the long-term outcomes for patients with left main CAD treated with PCI with drug-eluting stents vs. CABG; a state-of-the-art review on acute aortic syndrome; and the impact of heart disease subtypes on in-hospital mortality of patients with COVID-19.
Subscribe to Eagle’s Eye View
Drs. Deepak Bhatt, Payal Kohli, and Kim Eagle discuss highlights from the hottest clinical trials presented during Day 3 of the 2021 AHA Annual Scientific Session, including the PREPARE-IT 2 (0:32), AXIOMATIC-TKR (3:49), ASCEND (6:34), and REVERSE-IT (9:46) trials.
Subscribe to Eagle’s Eye View
Drs. Deepak Bhatt, Payal Kohli, and Kim Eagle discuss highlights from the hottest clinical trials presented during Day 2 of the 2021 AHA Annual Scientific Session, including trials EMPULSE (0:28), EMPEROR-Preserved (2:21), CHIEF-HF (4:05), and PALACS (7:43).
Subscribe to Eagle’s Eye View
Drs. Deepak Bhatt, Payal Kohli, and Kim Eagle discuss highlights from the hottest clinical trials presented during Day 1 of the 2021 AHA Annual Scientific Session, including trials on aortic valve replacement vs. watchful waiting in severe AS (AVATAR), and evaluating the benefit of concomitant tricuspid repair during mitral valve surgery (CTCR-MVS).
Subscribe to Eagle’s Eye View
In this View episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the hottest trials at the American Heart Association’s (AHA) Annual Scientific Sessions 2021 meeting held from November 13-15, including AVATAR, RAPID CABG, CHIEF-HF, EMPULSE, REVERSE-IT, AXIOMATIC-TKR, and many more.
Subscribe to Eagle’s Eye View
In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Roxana Mehran, and George Vetrovec discuss highlights from the hottest clinical trials presented during Day 3 of TCT 2021, including OPT-PEACE, SWISS-APERO, and Intrepid TMVR Early Feasibility.
Subscribe to Eagle’s Eye View
In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Roxana Mehran, and George Vetrovec discuss highlights from the hottest clinical trials presented during Day 2 of TCT 2021, including PRAGUE-17 and STOPDAPT-2 Total Cohort.
Subscribe to Eagle’s Eye View
In this special episode of Eagle’s Eye View, Drs. Deepak Bhatt, Roxana Mehran, and George Vetrovec discuss highlights from the hottest clinical trials presented during Day 1 of TCT 2021, including FAME 3, iFR-SWEDEHEART, and RADIANCE-HTN.
Subscribe to Eagle’s Eye View
This week’s View highlights perspectives from the newly released AHA/ACC Chest Pain Guideline. Access guideline-related resources, including expert commentary and key takeaways, the pocket guide, the Chest Pain Guideline Made Simple Tool, CardioSmart patient education, mobile apps and more on ACC’s Chest Pain Guideline Hub.
Subscribe to Eagle’s Eye View
In this View episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the hottest trials at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 meeting held from November 4-6, including FAME 3, RADIANCE-HTN, iFR-SWEDEHEART, SURTAVI, CHOICE-CLOSURE, AMULET IDE, PRAGUE-17, STOPDAPT-2, SWISS-APERO, GUIDE-HF, and TRISCEND.
Subscribe to Eagle’s Eye View
This week’s View analyzes the clinical factors that predict AFib in patients with recent embolic stroke of uncertain source, key points on a European Society of Cardiology (ESC) consensus document on antithrombotic therapies in aortic and peripheral arterial diseases, and ticagrelor monotherapy in patients at high bleeding risk undergoing PCI (TWILIGHT-HBR).
Subscribe to Eagle’s Eye View
This week’s View examines specific effects of systolic and diastolic blood pressure on various CV outcomes, the impact of hypertensive disorders of pregnancy on the onset of chronic hypertension in the first years following first pregnancy, and a look at how far we’ve come in contemporary PCI, a comparison of SYNTAX II versus SYNTAX I.
Subscribe to Eagle’s Eye View
This week’s View focuses on hypertension treatment intensification in older adults, key points on physical activity and exercise in patients with spontaneous coronary artery dissection and fibromuscular dysplasia, and CV disease risk among cigarette smokers who transitioned to vaping.
Subscribe to Eagle’s Eye View
This week’s View focuses on prevention: the association of statin therapy initiation and diabetes progression, the relationship between target BP and outcomes in patients with left ventricular hypertrophy, and the effects of lifestyle modifications in patients with resistant hypertension.
Subscribe to Eagle’s Eye View
This week’s View focuses on the effect of neprilysin inhibition on BP in patients with HFpEF and resistant hypertension, three- vs. two-drug therapy for patients with newly diagnosed pulmonary artery hypertension, and early invasive angiography in acute HF.
This week's View summarizes articles on empagliflozin improving CV outcomes irrespective of blood pressure, the efficacy of the COVID-19 vaccine at 6 months post-vaccination, and the protection of the COVID-19 booster dose in Israel.
This week’s View summarizes articles about whether there are differences in daily symptom scores on statin, placebo, and no treatment in participants who had abandoned statins; the safety and immunogenicity of heterologous schedules with different coronavirus disease 2019 (COVID-19) vaccines; and the effectiveness of inhaled budesonide in reducing recovery time and rates of COVID-19-related hospital admission or death in people at high risk of an adverse outcome.
This week’s View summarizes articles about whether acute alcohol consumption increases the risk of a discrete atrial fibrillation (AF) episode, whether continuous cardiac rhythm monitoring beyond hospital discharge enhances AF detection among cardiac surgical patients, and if the addition of aspirin in fixed-dose combination treatment is associated with reductions for cardiovascular disease outcomes.
In this special episode of Eagle’s Eye View, Dr. Deepak Bhatt, Dr. Gabriel Steg, and Dr. Carolyn Lam discuss highlights from Day 4 of ESC Congress 2021, including IAMI, STEP, Amulet IDE, PRONOUNCE, and STOPDAPT-2 ACS.
In this special episode of Eagle’s Eye View, Dr. Deepak Bhatt and Dr. Gabriel Steg discuss highlights from Day 3 of ESC Congress 2021, including TWILIGHT-HBR, The Michelle Trial, ECLA PHRI COLCOVID, and PREPARE-IT.
In this special episode of Eagle’s Eye View, Dr. Deepak Bhatt and Dr. Gabriel Steg discuss highlights from Day 2 of ESC Congress 2021, including MASTER DAPT, ENVISAGE-TAVI AF, and FIGARO-DKD.
In this special episode of Eagle’s Eye View, Dr. Deepak Bhatt, Dr. Gabriel Steg, and Dr. Carolyn Lam discuss highlights from Day 1 of ESC Congress 2021, including EMPEROR-Preserved, EMPEROR-Pooled, GUIDE-HF, and the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
This week’s View offers key points from a state-of-the-art review on management of acute cardiovascular complications in pregnancy, summarizes an article about pregnancy-associated vascular complications in Marfan syndrome, and analyzes a subgroup analysis looking at the risk for major adverse cardiovascular events in relation to prior acute coronary syndrome and the benefits of colchicine.
In this week’s View, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the hottest trials at the European Society of Cardiology Congress 2021, taking place virtually August 27-30, including IAMI, EMPEROR-Preserved, EMPEROR-Pooled, MASTER DAPT, ENVISAGE-TAVI AF, FIGARO-DKD, FIDELITY, Colchicine in Patients Hospitalized with COVID-19, PREPARE-IT, The Michelle trial, GUIDE-HF, QUARTET, TWILIGHT-HBR, PRONOUNCE, and Amulet IDE.
This week’s View covers articles about the features and outcomes of post-vaccination cerebral venous thrombosis with and without vaccine-induced thrombotic thrombocytopenia, whether a Mediterranean dietary pattern reduces atherosclerosis among patients with established coronary heart disease, and the natural history of asymptomatic penetrating aortic ulcer.
In this week’s View, guest host Deepak Bhatt, MD, MPH, FACC, reviews articles about the risk of acute myocardial infarction and ischemic stroke associated with coronavirus disease 2019 (COVID-19) among all COVID-19 cases in Sweden, a sub-analysis from the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial, and whether the cumulative intake of a plant-centered diet is associated with incident cardiovascular disease.
In this week’s View, guest host Deepak Bhatt, MD, MPH, FACC, reviews articles about the trends and hospital variation in same-day discharge following elective percutaneous coronary intervention, the frequency of heart failure diagnosis in the acute care setting versus the outpatient setting, and whether smoking cessation affects overall and progression-free survival and the risk for all-cause and lung cancer-specific mortality after a diagnosis of lung cancer.
This week’s View covers articles about the association of low-level alcohol consumption and incident atrial fibrillation in middle-aged adults and the effectiveness of Pfizer-BioNTech and AstraZeneca vaccines against symptomatic disease caused by the severe acute respiratory syndrome coronavirus 2 delta variant and offers key points from an ACC Expert Consensus Decision Pathway on the management of atherosclerotic cardiovascular disease risk reduction in patients with persistent hypertriglyceridemia.
This week’s View covers articles about whether there is an association between the use of fluoroquinolones and an increased risk of aortic or mitral regurgitation; whether a new classification of response, based on reverse remodeling and the clinical composite score, better predicts survival after cardiac resynchronization therapy; and the clinical profiles, discharge medical therapies, and in-hospital mortality among patients hospitalized for heart failure across the spectrum of kidney function.
This week’s View summarizes a review article about established and emerging indications for sodium-glucose luminal cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, a scientific statement from the American Heart Association on the diagnosis and management of myocarditis in children, and a global consensus statement on transition to adulthood and transfer to adult care of adolescents with congenital heart disease.
In this week’s View, guest host Deepak Bhatt, MD, MPH, FACC, reviews articles about the impact of ischemic burden reduction after chronic total occlusion percutaneous coronary intervention (PCI) on long-term prognosis and cardiac symptom relief, the relationship between operator PCI using rotational atherectomy volumes and in-hospital patient outcomes, and the impact of age on the safety and efficacy of ticagrelor monotherapy after PCI.
This week’s View offers key points to remember from an American Heart Association Scientific Statement on obstructive sleep apnea and cardiovascular disease, the Kidney Disease: Improving Global Outcomes 2021 clinical practice guideline for the management of blood pressure in patients with chronic kidney disease not receiving dialysis, and a state-of-the-art review on the genetics of adult-onset dilated cardiomyopathy.
This week’s View summarizes articles about the characteristics of patients with myocarditis temporally correlated with severe acute respiratory syndrome coronavirus 2 vaccination, differences in coronavirus disease 2019 hospital mortality rates between Black and White patients attributable to patient characteristics and hospital factors, and the validity of SCORE2 to estimate 10-year fatal and nonfatal cardiovascular disease risk in individuals in Europe without previous CVD or diabetes aged 40-69 years.
This week’s View summarizes articles about the prevalence and clinical significance of aortic branch aneurysms in patients with Marfan syndrome, whether triglyceride levels are associated with subclinical atherosclerosis and vascular inflammation regardless of low-density lipoprotein cholesterol, and the clinical outcomes associated with the use of 4-factor prothrombin complex concentrates, idarucizumab, or andexanet alpha for reversal of severe direct oral anticoagulant-associated bleeding.
This week’s View summarizes articles about how prevalent left atrial thrombus is in patients with atrial fibrillation or flutter who are on guideline-directed anticoagulation, the natural history of symptoms and ischemia in patients with ischemia with no obstructive coronary artery disease, and the characteristics and prognosis of patients with microvascular angina.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles on the effectiveness of same-day rapid antigen detection testing for severe acute respiratory syndrome coronavirus 2 for reducing the incidence of infection after social indoor gatherings; the safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents; and the prevalence of myocarditis in athletes with COVID-19 and screening strategies for safe return to play.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles on the incidence of venous thromboembolism and major bleeding in critically ill patients with COVID-19, the proportion of people with a positive severe acute respiratory syndrome coronavirus 2 test who are asymptomatic, and the safety and efficacy of high-titer convalescent plasma therapy in patients admitted to the hospital with COVID-19.
This week’s View highlights nine of the hottest trials presented at ACC.21: LAAOS III, ADAPTABLE, EXPLORER-HCM, FLOWER-MI, HOST-EXAM, DARE-19, REHAB-HF, FIDELIO-DKD, and GALACTIC-HF.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli discuss highlights from Day 3 of ACC.21, including SOLOIST and SCORED, LIFE, GALACTIC-HF, FIDELIO-DKD, and RESCUE.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli discuss highlights from Day 2 of ACC.21, including FLOWER-MI, DARE-19, COALITION ACTION, REHAB-HF, HOST-EXAM, and RADIANCE-HTN TRIO.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Deepak Bhatt, and Dr. Payal Kohli discuss highlights from Day 1 of ACC.21, including LAAOS III, ATLANTIS, ADAPTABLE, EXPLORER-HCM, and PARADISE-MI.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles about the ethnic differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 outcomes during the first and second waves of the COVID-19 pandemic in England, the diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced thrombotic thrombocytopenia, and the effectiveness of the mRNA BNT162b2 vaccine against SARS-CoV-2 infections, COVID-19 hospitalizations, and deaths.
In this week’s View, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the hottest trials at ACC's 70th Annual Scientific Session (ACC.21), streaming live May 15-17, including ADAPTABLE, PARADISE-MI, DARE-19, ATLANTIS, ATLANTIS-4D-CT, LAAOS III, FLOWER-MI, RAFT-AF, ISCHEMIA, TAILOR-PCI, REALITY, FIDELIO-DKD, and HOLIDAY Monitors.
This week’s View focuses on the coronavirus disease 2019 resources on ACC.org, including articles about whether mass vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a reduction in hospitalizations for coronavirus disease 2019 (COVID-19), how patients presented with cerebral venous sinus thrombosis and thrombocytopenia following receipt of the Ad26.COV2.S COVID-19 vaccine, and how the SARS-CoV-2 infection rate in health care workers with previous exposure to SARS-CoV-2 compares to the infection rate in nonexposed health care workers.
This week’s View focuses on the coronavirus disease 2019 resources on ACC.org, including articles about the case characteristics for individuals who have clinically recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but continued to have positive test results following discontinuation of isolation precautions and the prevalence and clinical implications of SARS-CoV-2 cardiac involvement in young competitive athletes.
This week’s View discusses adverse events that have occurred after receipt of the severe acute respiratory syndrome coronavirus 2 vaccination and offers key points from the 2020 European Society of Cardiology guidelines for the management of non-ST-elevation acute coronary syndromes and a Scientific Statement from the American Heart Association/American Stroke Association on perioperative neurological evaluation and management to lower the risk of acute stroke in patients undergoing noncardiac surgery.
In this episode, Kim Eagle, MD, MACC, asks Matthew Martinez, MD, FACC, and Steve Ommen, MD, FACC, all of the questions you wish you could ask about hypertrophic cardiomyopathy and the new ACC guidelines.
In this week's View, guest host Deepak Bhatt, MD, MPH, FACC, discusses trends in in-hospital mortality among patients who tested positive for severe acute respiratory syndrome coronavirus 2, the incidence of cardiovascular disease, death, or heart failure among patients with human immunodeficiency virus and hypertension, and recent updates from the DAPA-CKD and EMPEROR-Reduced trials.
In this week's View, guest host Deepak Bhatt, MD, MPH, FACC, offers key points to remember from a American Heart Association Scientific Statement on adverse pregnancy outcomes and cardiovascular disease risk and summarizes articles on the effectiveness of the Oxford/AstraZeneca ChAdOx1 vaccine against the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 and the clinical benefit of low-dose colchicine when added to guideline-based treatment in patients with recent myocardial infarction or chronic coronary disease.
This week's View summarizes articles focusing on prevention: whether low levels of lipoprotein(a) and corresponding lipoprotein(a) genotypes are associated with major disease groups, the relative incidence and mortality risk for cardiovascular diseases among people with different types of diets using data from the UK Biobank, and the association between alcohol consumption, biomarkers, and incident atrial fibrillation across the spectrum of alcohol intake in European cohorts.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including key points from the American College of Physicians on the antibody response and role in conferring natural immunity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and summaries of articles on whether ABO and rhesus blood groups are associated with risk of SARS-CoV-2 infection and severe COVID-19 and the characteristics, diagnostics, and outcomes of patients with acute ischemic stroke and COVID-19 in the United States.
This week’s View offers key points to remember from the American Heart Association Scientific Statement on invasive management of acute myocardial infarction complicated by cardiogenic shock and summarizes articles about the association of age with the likelihood of both developing symptoms and progressing to critical illness after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the optimal planned delay before surgery in patients who have had SARS‐CoV‐2 infection.
This week’s View covers articles about the implication of a very high coronary artery calcium score for cardiovascular disease (CVD), non-CVD, and mortality risks in primary prevention versus secondary prevention populations, whether beta-blockers are cardioprotective among patients with stable, optimally treated myocardial infarction without heart failure, and the prevalence of clinically detectable inflammatory heart disease in professional athletes with prior coronavirus disease 2019 infection.
This week’s View covers articles about the rates of antiarrhythmic drug and catheter ablation use for the management of paroxysmal atrial fibrillation (AF) in terms of race/ethnicity and socioeconomic status, whether socioeconomic factors and sex differences play a role in changing trends in AF incidence and mortality, and the relationship between the renin-angiotensin-aldosterone system and ambulatory blood pressure (ABP) and ABP monitoring phenotypes among African Americans.
This week’s View covers articles about cardiovascular magnetic resonance evaluation of myocardial injury in patients with troponin-positive coronavirus disease 2019 (COVID-19), dose timing and variations in the efficacy of the ChAdOx1 nCoV-19 vaccine in reducing the risk of symptomatic COVID-19, and the 3-year outcomes of transcatheter mitral valve repair in patients with heart failure and functional mitral regurgitation.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including key points from a recent guidelines document on the use of remdesivir to treat COVID-19, a Health Policy Statement on the impact of cardiovascular risk factors and comorbidities on COVID-19, and a recent article on the prevalence of severe acute respiratory syndrome coronavirus 2 in asymptomatic participants in a university community.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including recent articles on the S protein subunit severe acute respiratory syndrome coronavirus 2 vaccine candidate, out-of-hospital and in-hospital cardiac arrest cardiac arrest cases with COVID-19 during pre-pandemic and pandemic periods, and use of treatment-dose anticoagulation in patients hospitalized with COVID-19.
This week’s View offers key points from a recommendation statement on screening for asymptomatic carotid artery stenosis and a consensus document on the impact of gynecological and obstetric conditions on cardiovascular health and summarizes a study comparing coronavirus disease 2019-related outcomes in health care workers versus than the general population.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including recently published articles on the impact of bamlanivimab with or without etesevimab on severe acute respiratory syndrome coronavirus 2 viral load in mild to moderate COVID-19, the current state of COVID-19 vaccines, and the rate of anaphylactic reactions following one’s first dose of the Pfizer-BioNTech COVID-19 vaccine.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including recently published articles on the difference in sensitivity and cost for severe acute respiratory syndrome coronavirus 2 detection between nasopharyngeal swabs and saliva testing, the effect of discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the number of days alive and out of the hospital in patients with COVID-19, and the corrected QT prolongation in a cohort of patients hospitalized with COVID-19 treated with combination hydroxychloroquine and azithromycin.
This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including recently published articles on the estimated proportion of severe acute respiratory syndrome coronavirus 2 transmissions that occur from asymptomatic individuals and how the COVID-19 pandemic has affected population-level cardiovascular deaths in the United States and global cardiovascular diagnostic procedural volumes and safety practices.
This week’s View goes over key perspectives from the 2020 American College of Cardiology (ACC) and American Heart Association (AHA) guideline for the management of patients with valvular heart disease, which replaces the ACC/AHA 2014 guideline and the 2017 focused update.
In this special episode of the View, Deepak Bhatt, MD, MPH, FACC, joins Kim Eagle, MD, MACC, to discuss the top journal scans and clinical trials from 2020.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including a summary of a trial to assess the safety and efficacy of hydroxychloroquine as post-exposure prophylaxis for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and three articles on mortality in patients with COVID-19 across the United States, the patterns of viral polymerase chain reaction positivity and their correlations with seroconversion and disease severity, and the safety and effectiveness of the ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles questioning how comorbidities and neighborhood characteristics impact race-related COVID-19 outcomes, Key Points to Remember from an expert consensus statement on screening of potential cardiac involvement in competitive athletes recovering from COVID-19, and WHO Solidarity trial assessing the safety and efficacy of four drugs (remdesivir, hydroxychloroquine, lopinavir, interferon) among patients hospitalized with COVID-19.
Subscribe on Apple Podcasts | Subscribe on Google Play
This week's View reviews recent journal articles about the prognostic importance of the transmitral mean pressure gradient and the presence of mitral regurgitation among patients with mitral annular calcification, the effect of beta-blockers on respiratory function and survival in patients with chronic obstructive pulmonary disease and cardiovascular disease, and the distribution of race/ethnicity in cases of multisystem inflammatory syndrome in children reported in New York City.
This week's View offers key perspectives from the newly released 2020 American Heart Association/American College of Cardiology guideline for the management of patients with hypertrophic cardiomyopathy.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 5 of AHA 2020, including results from the INVESTED trial.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 4 of AHA 2020, including SEARCH-AF, FIDELIO, THALES, RHAPSODY, SOLOIST-WHF, and SCORED.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle and Dr. Deepak Bhatt discuss highlights from Day 3 of AHA 2020, including STRENGTH, OMEMI, EXPLORER-HCM, One-Month DAPT, and COLCOT Diabetes.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle and Dr. Deepak Bhatt discuss highlights from Day 1 of AHA 2020, including GALACTIC-HF, AFFIRM-AHF, VITAL-Rhythm, ARREST, TIPS-3, DAPA-CKD, and EMPEROR-Reduced.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle and Dr. Deepak Bhatt discuss highlights from Day 2 of AHA 2020, including ALPHEUS and RIVER.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles about the estimated number of adults with risk factors for COVID-19 who either are or live with essential workers, the impact of the COVID-19 pandemic on clinical outcomes among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, and the clinical outcomes during and immediately following hospitalization for COVID-19 among patients with a prior diagnosis of heart failure.
In this week’s View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at AHA 2020, taking place virtually November 13-17, including GALACTIC-HF, SOLOIST-WHF, SCORED, EMPATROPISM, STRENGTH, OMEMI, ATLANTIS, SEARCH-AF, INVESTED, and RHAPSODY.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles about whether treatment with viral-neutralizing monoclonal antibodies reduces viral load in outpatients with mild to moderate COVID-19, the cardiovascular magnetic resonance findings in patients with cardiac symptoms following recovery from COVID-19, and whether right ventricular longitudinal strain is an independent predictor of mortality in patients with COVID-19.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including key points from a review of studies addressing the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an article on the clinical utility of antibody testing for SARS-CoV-2, and a trial evaluating hydroxychloroquine compared with placebo among nonhospitalized patients with confirmed or probable COVID-19 infection.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including summaries of ACTT-1 (Adaptive COVID-19 Treatment Trial) and the RECOVERY (Lopinavir–Ritonavir) and RECOVERY (Hydroxychloroquine) trials (Randomized Evaluation of COVID-19 Therapy).
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 4 and Day 5 of TCT 2020, including Anatomy of Human Accessory Renal Artery Peri-Arterial Renal Sympathetic Nerve for Renal Denervation and IREMMI.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 3 of TCT 2020, including DEFINE-FLOW, REFLECT II, and STS/ACC TVT Registry.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 2 of TCT 2020, including Disrupt CAD III, SCOPE II, and ULTIMATE.
In this special episode of Eagle’s Eye View, Dr. Kim Eagle, Dr. Peter Block, and Dr. Deepak Bhatt discuss highlights from Day 1 of TCT 2020, including PROSPECT ABSORB and TICO-STEMI.
In this week’s View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at TCT 2020, taking place virtually October 14-18, including PROSPECT ABSORB, COMPARE CRUSH, TICO-STEMI, SCOPE II, REFLECT II, Disrupt CAD III, XIENCE 90, XIENCE 28, ULTIMATE, SOLVE-TAVI, COBRA-REDUCE, VOYAGER PAD, and IN.PACT BTK.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including key points from articles about the Emergency Use Authorization for the use of convalescent plasma to treat COVID-19; the potential cardioprotective effects of influenza vaccines in the context of the COVID-19 pandemic; the risk factors, incidence, and outcomes associated with in-hospital cardiac arrest and cardiopulmonary resuscitation in critically ill adults with COVID-19; and the observed mortality incidence among patients with COVID-19 within 90 days of receiving extracorporeal membrane oxygenation support.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including an article about the in-hospital cardiac arrest survival to discharge in patients with COVID-19, an article about how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and test results have differed between English-speaking and non-English-speaking patients, and key points from a systematic review of the transmission of SARS-CoV-2.
This week's View covers an article about how strategic changes in recipient and donor selection impact center-level heart transplant outcomes, key points to remember from an American Heart Association Scientific Statement on drug-induced arrhythmias, and an article about whether certain biomarkers improve prognostication in patients hospitalized with coronavirus disease 2019.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including an article about the risk factors associated with development of PE in patients hospitalized for COVID-19, an article about whether cardiac magnetic resonance imaging identifies competitive collegiate athletes recovered from COVID-19 infection who are at higher risk for return to play, and a trial that assessed whether adding azithromycin to standard of care that included hydroxychloroquine would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.
This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including a trial comparing low-dose corticosteroids with placebo among patients with COVID-19 infection and acute respiratory failure, a trial comparing corticosteroids with usual care among patients with moderate to severe COVID-19 infection, and an article about whether the administration of systemic corticosteroids is associated with reduced 28-day mortality in critically ill patients with COVID-19.
In this special episode of Eagle's Eye View, Dr. Deepak Bhatt, Dr. Kim Eagle, and Dr. Gabriel Steg discuss highlights from Day 4 of ESC Congress 2020, including THEMIS-PAD, BRACE CORONA, and REALITY.
In this special episode of Eagle's Eye View, Dr. Deepak Bhatt, Dr. Kim Eagle, and Dr. Gabriel Steg discuss highlights from Day 3 of ESC Congress 2020, including HOME-PE and LoDoCo2.
In this special episode of Eagle's Eye View, Dr. Deepak Bhatt, Dr. Kim Eagle, and Dr. Gabriel Steg discuss highlights from Day 2 of ESC Congress 2020, including VOYAGER PAD, BAMI, ATPCI, POPULAR TAVI, PARALLAX, and DAPA-CKD.
In this special episode of Eagle's Eye View, Dr. Deepak Bhatt, Dr. Kim Eagle, and Dr. Gabriel Steg discuss highlights from Day 1 of ESC Congress 2020, including COLCOT, COPS, EVAPORATE, EMPEROR-Reduced, EAST – AFNET 4, and EXPLORER-HCM.
This week's View summarizes two recent publications, one a trial showing that a 5-day course of remdesivir was superior to standard therapy at improving clinical status among patients with moderate coronavirus disease 2019 infection, and the other a prespecified secondary analysis within the PARAGON-HF trial looking at the impact of angiotensin-neprilysin inhibition on renal events among patients with heart failure with preserved ejection fraction.
In this special episode of Eagle's Eye View, Dr. Peter Block and Dr. Deepak Bhatt discuss highlights from Day 3 of ACC.20/WCC Virtual, including TICO, TWILIGHT Diabetes and TWILIGHT-COMPLEX Substudies, Radial Artery Versus Saphenous Vein for Coronary Bypass Surgery at Long-Term Follow-Up, PRECOMBAT, and REDUCE-IT EPA.
In this special episode of Eagle’s Eye View, Dr. Peter Block and Dr. Deepak Bhatt discuss highlights from Day 1 of ACC.20/WCC Virtual, including VICTORIA, VOYAGER PAD, COMPASS Diabetes, and TAILOR PCI.
Part 2 of this week's View focuses on the COVID-19 pandemic and the resources available on ACC.org, including key points to remember from an article on the case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, an article on whether troponin levels can predict clinical severity of patients with COVID-19 infection, and an article on the association between COVID-19 and morbidity and mortality from cardiovascular disease.
Part 1 of this week's View focuses on the COVID-19 pandemic and the resources available on ACC.org, in particular an article on the clinical course and risk factors for mortality in adult patients admitted with coronavirus disease 2019 (COVID-19) infection, based on the experience from Wuhan, China, and key points to remember from an article about coronaviruses and the cardiovascular system.
In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at ACC's Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) Virtual, taking place online only March 28-30, including VICTORIA, VOYAGER PAD, COMPASS, TAILOR PCI, SPYRAL HTN-OFF MED PIVOTAL, TWILIGHT, TICO, E3, REDUCE-IT, and ISCHEMIA.
This week's View includes discussion of the comparative safety and effectiveness of apixaban versus rivaroxaban for patients with nonvalvular atrial fibrillation, the early and late outcomes between redo surgical aortic valve replacement and valve-in-valve transcatheter aortic valve replacement for failed biological prostheses, and predictive value of a multimarker panel for risk of death and hospitalization for patients with heart failure with preserved ejection fraction.
This week's View explores the optimal method of revascularization for left main coronary artery disease, summarizes key points to remember from a state-of-the-art review on diuretic therapy for patients with heart failure, and examines cardiovascular magnetic resonance for patients with immune checkpoint inhibitor-associated myocarditis.
This week's View explores whether olive oil intake is associated with total cardiovascular disease, coronary heart disease, and stroke risk; summarizes key points to remember from the European Heart Rhythm Association international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections; and examines how short-term outcomes differ for transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic valve.
This week's View covers a study that applied the 2019 European Society of Cardiology and European Atherosclerosis Society guidelines to data of patients with recent myocardial infarction (MI) and a study on the time trends of in-hospital and out-of-hospital bleeding parallel to the development of new treatments and ischemic outcomes over the last 20 years in a nationwide MI population.
In this week's View, guest host Dr. Deepak Bhatt gives us an update from the SOLVE-TAVI trial; talks about the diagnostic performance of FFRangio, an angiogram-derived fractional flow reserve technology; and introduces the HUNT study, which looked at physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation.
This week's View delves into how cardiovascular events are reported in clinical trials of contemporary cancer therapies, the risk of occult colorectal cancer in patients with atrial fibrillation treated with oral anticoagulation therapy who experience gastrointestinal bleeding, and the long-term safety and efficacy data for evolocumab in patients with homozygous and heterozygous familial hypercholesterolemia.
This week's View discusses the accuracy of coronary computed tomography angiography to identify coronary artery disease in patients with non-ST-segment elevation acute coronary syndrome and summarizes the 5-year outcomes of the PARTNER 2A trial and new results from a substudy of the DECLARE–TIMI 58 trial.
This week's View goes over key points to remember from the 2019 European Society of Cardiology and European Respiratory Society guidelines for the diagnosis and management of acute pulmonary embolism, the clinical implications and prognostic significance of abnormal (positive) exercise electrocardiography but normal stress echocardiography, and the structural and functional echocardiographic phenotypes across the spectrum of wild-type and hereditary transthyretin cardiomyopathy.
This week's View outlines key points to remember from a review on embolic stroke of undetermined source, discusses whether malignant left ventricular hypertrophy contributes to racial disparities in heart failure risk, and looks at the evolution of early outcomes for three iterative self-expanding transcatheter aortic valves.
This week's View goes over key points to remember from a state-of-the-art review on peripartum cardiomyopathy, updates from EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), and key points to remember from the 2019 European Society of Cardiology and European Association for the Study of Diabetes guidelines on diabetes, pre-diabetes, and cardiovascular diseases.
This week's View offers key points from an article on fractional flow reserve in clinical practice, discusses whether preoperative N-terminal pro-B-type natriuretic peptide measurements can improve prediction of adverse postoperative cardiovascular outcomes in a very large surgical population, and summarizes updated 5-year outcomes of NOBLE (Nordic–Baltic–British Left Main Revascularisation Study).
This week's View presents highlights from ACC.org this year, including the ISCHEMIA and DAPA-HF trials, an article comparing the durabilities of transcatheter and surgical bioprosthetic aortic valve replacement (AVR), an article on safety and efficacy of a D-dimer threshold for diagnoses of pulmonary embolism, and an article discussing the impact of anticoagulation therapy after AVR on valve hemodynamics and clinical outcomes.
This week's View summarizes an article on the outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome who are treated with percutaneous coronary intervention, an article on the patient and health system-level factors associated with hospital readmission within 90 days after acute stroke, and a trial that showed that an angiotensin receptor blocker was superior to placebo at slowing aortic root dilatation in patients with Marfan syndrome.
This week's View explores the effectiveness of combination diuretic regimens to overcome loop diuretic resistance in acute heart failure; the association among race and disease expression, care provision, and clinical outcomes among patients with hypertrophic cardiomyopathy; and the optimal strategy for antiplatelet therapy in patients with lower extremity peripheral artery disease after endovascular revascularization.
This week's View analyzes whether the criteria for left bundle branch block influence the response rate to cardiac resynchronization therapy, the association between trends in primary and secondary vascular access sites and vascular access site complications among patients who underwent percutaneous coronary intervention, and the safety and efficacy of a D-dimer threshold for diagnoses of pulmonary embolism based on clinical probability.
In this special episode of the View, Dr. Peter Block, Dr. Kim Eagle, and Dr. Deepak Bhatt discuss highlights from Day 2 of AHA.19, including the effect of treatment according to age in the DAPA-HF trial, early surgery versus conventional management for asymptomatic severe aortic stenosis in the RECOVERY trial, and results from the 3,146 patients randomized in the United States in the REDUCE-IT USA trial.
In this special episode of the View, Dr. Peter Block and Dr. Deepak Bhatt discuss highlights from Day 1 of AHA.19, including the Dapagliflozin and Prevention of Adverse-Outcomes in HF Trial (DAPA-HF), the Colchicine Cardiovascular Outcomes Trial (COLCOT), and the International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches (ISCHEMIA) trials.
This week's View examines the association of sex with patient outcomes at 2 years after contemporary percutaneous coronary intervention; the determinants, rate, and consequences of progression of aortic regurgitation; and the association and burden of coronary artery calcium with long-term cause-specific mortality across the spectrum of baseline risk.
In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at the American Heart Association Scientific Sessions 2019, taking place November 16-18 in Philadelphia, PA, including ISCHEMIA, ISCHEMIA QoL, ISCHEMIA-CKD, DAPA-HF, COLCOT, Treat Stroke To Target, REDUCE-IT Cost-Effectiveness, REDUCE-IT USA, EVAPORATE, PARADIGM-HF, and PARAGON-HF.
This week's View covers key points to remember from a comparison of the US and European guidelines for the diagnosis and management of syncope; the incorporation of cardiac magnetic resonance, genetic, and biomarker data to enable identification of distinct subgroups within the Hypertrophic Cardiomyopathy Registry; and differences in outcome by primary antihypertensive agents among the first-line drug classes.
This week's View offers key points to remember from an opinion article on the current diagnostic criteria and differential diagnosis of arrhythmogenic right ventricular cardiomyopathy and a consensus statement on the diagnosis of heart failure (HF) with preserved ejection fraction (EF) and also addresses how sacubitril/valsartan impacts certain biomarker levels compared with enalapril in patients with HF and reduced EF.
This week's View summarizes the 10-year follow-up of the SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) and offers key points to remember from an article about lipid management for the prevention of atherosclerotic cardiovascular disease and a state-of-the-art review on the clinical and prognostic significance of soluble suppression of tumorigenesis-2 in heart failure.
This week's View examines the patterns of treatment changes and consistency of reduced adverse events in patients with stable chest pain undergoing coronary computed tomography angiography, the risk of osteoporotic fractures in patients with atrial fibrillation treated with vitamin K antagonists versus direct oral anticoagulants, and whether there is an increase in mortality after use of paclitaxel-based drug-eluting devices in peripheral arteries.
This week's View explores the benefit of uninterrupted direct oral anticoagulant versus uninterrupted vitamin K antagonist use for patients undergoing catheter ablation for nonvalvular atrial fibrillation; which therapy, anticoagulation or antiplatelet, is better for preventing stroke recurrence in patients with patent foramen ovale and a history of stroke or transient ischemic attack; and more.
This week's View takes a look at which patients without known cardiovascular disease are most likely to experience net benefit from aspirin therapy for primary prevention, the outcomes with angioplasty with paclitaxel-coated balloon versus repeat stenting with drug-eluting stent in patients undergoing treatment for in-stent restenosis, and key points to remember from a JACC Review Topic of the Week on the cardiovascular toxicities of immune checkpoint inhibitors.
In this special episode of the View, Dr. Peter Block and Dr. Anthony DeMaria discuss highlights from Day 4 of TCT.19, including the cost-effectiveness analysis from MitraClip in heart failure and severe secondary mitral regurgitation (COAPT Cost-Effectiveness Analysis) and health status outcomes from transcatheter aortic valve replacement vs. surgical aortic valve replacement in severe aortic stenosis patients at low-surgical risk (PARTNER 3).
In this special episode of the View, Dr. Peter Block and Dr. Anthony DeMaria discuss highlights from Day 3 of TCT.19, including MitraClip in heart failure and severe secondary mitral regurgitation (COAPT Three-Year Outcomes), transcatheter aortic valve replacement vs. surgical aortic valve replacement in intermediate-risk severe aortic stenosis (PARTNER 2A), percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting left main coronary artery disease (EXCEL), and more.
In this special episode of the View, Dr. Peter Block and Dr. Spencer King discuss highlights from Day 1 of TCT.19, including apixaban vs. warfarin and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndromes (AUGUSTUS ACS) and ticagrelor monotherapy vs. ticagrelor-plus-aspirin in high-risk percutaneous coronary intervention (TWILIGHT).
In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at TCT 2019, taking place September 25-29 in San Francisco, CA, including TWILIGHT, AUGUSTUS ACS, PORTICO, PARTNER 3 Low-Risk Computed Tomography Substudy, Three-Year Outcomes from COAPT, Five-Year Outcomes from PARTNER 2A, Five-Year Outcomes from EXCEL, COMPLETE Timing Substudy, Cost-Effectiveness Analysis from COAPT, Health Status Outcomes from PARTNER 3, and Five-Year Outcomes from IVUS-XPL.
This week's View discusses the outcomes of complete neonatal repair compared with staged procedure for neonates with tetralogy of Fallot, the outcomes of transcatheter aortic valve replacement versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis, and key points to remember from the 2019 ESC/EAS guidelines for the management of dyslipidemias.
This week's View outlines key points to remember from two new European Society of Cardiology (ESC) guidelines: the 2019 ESC guidelines for the management of patients with supraventricular tachycardia and the 2019 ESC and European Respiratory Society guidelines for the diagnosis and management of acute pulmonary embolism.
In this special episode of the View, Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss Day 4 of ESC Congress 2019, including genotype-guided oral P2Y12-inhibition in patients with ST-segment elevation myocardial infarction undergoing primary PCI (POPular Genetics); edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients (ENTRUST-AF PCI); and more.
In this special episode of the View, Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss Day 3 of ESC Congress 2019, including rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease (AFIRE); effects of sacubitril-valsartan compared with enalapril on arterial hemodynamics and cardiac remodeling in patients with heart failure and reduced ejection fraction (EVALUATE-HF, PROVE-HF); and more.
In this special episode of the View, Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss Day 2 of ESC Congress 2019, including ticagrelor compared to placebo added to low-dose aspirin in patients with stale coronary artery disease (THEMIS and THEMIS-PCI); angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction and dapagliflozin and prevention of adverse outcomes in heart failure (PARAGON-HF and DAPA HF); and more.
In this special episode of the View, Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss Day 1 of ESC Congress 2019, including objective risk assessment versus standard care for acute coronary syndromes (AGRIS); the relationship between hypoglycemia, cardiovascular outcomes, and empagliflozin treatment (EMPA-REG OUTCOME); and maximum-fixed energy versus low-escalating energy shocks for cardioversion of atrial fibrillation (CHESS).
This week's View explores the impact of anticoagulation therapy after bioprosthetic aortic valve replacement on valve hemodynamics and clinical outcomes, the relative clinical benefit of adding alirocumab to statins in acute coronary syndrome patients with prior coronary artery bypass grafting, and whether the achievement of N-terminal pro-B-type natriuretic peptide to ≤1000 pg/ml at 90 days with guideline-directed medical therapy predicts outcomes.
In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at ESC Congress 2019, taking place August 31-September 4 in Paris, including ASCEND, THEMIS, THEMIS-PCI, PARAGON-HF, COMPLETE, HERMES, Combined effect of lower LDL-C and lower SBP on the lifetime risk of cardiovascular disease, GALACTIC, ENTRUST-AF PCI, and POPular Genetics.
This week's View, guest hosted by Dr. Deepak Bhatt, investigates whether biomarkers can be used to identify subsets of patients post-acute coronary syndrome who would benefit best from adjunctive ezetimibe treatment, addresses the late results of mitral valve repair for mitral regurgitation due to mitral valve prolapse, and offers key points from the JACC Scientific Expert Panel opinion on the management of conduction disturbances associated with transcatheter aortic valve replacement.
This week's View examines the relationship between clinically assessed left ventricular (LV) ejection fraction and survival in a large, heterogeneous clinical cohort, how a focused cardiac ultrasound performs in comparison to clinical assessment alone for diagnosis of LV systolic dysfunction and valvular heart disease, and the efficacy and safety of oral labetalol, nifedipine, and methyldopa for the management of severe hypertension in pregnancy.
This week's View, guest hosted by Dr. Deepak Bhatt, explores the incidence of sudden cardiac death among persons living with human immunodeficiency virus infection with heart failure, the effect of metformin on cardiovascular outcomes and all-cause mortality in patients with type 2 diabetes mellitus, the amputation-free survival and reintervention rates in patients treated with initial open surgical bypass or endovascular intervention for ischemic ulcers of the lower extremities, and more.
This week's View, guest hosted by Dr. Deepak Bhatt, explores the impact of prolonged spaceflight on orthostatic tolerance and blood pressure profile in astronauts, the prevalence of atrial fibrillation in former National Football League athletes compared with population-based controls, whether composite cardiovascular events are more prevalent in patients with rejected/abandoned proprotein convertase subtilisin kexin type 9 inhibitor prescriptions than in those whose prescriptions are paid, and more.
This week's View covers the diagnostic performance, safety, and efficiency of a single high-sensitivity cardiac troponin I measurement strategy to identify patients at low and high risk for acute myocardial infarction, the independent association between young adult exposures to risk factors and later life cardiovascular disease risk, and key points to remember from a state-of-the-art review on coronary artery disease and transcatheter aortic valve replacement.
This week's View looks at the prognosis after myocardial infarction (MI) with nonobstructive coronary arteries versus acute MI with obstructive coronary artery disease among patients ages ≥65 years, the 1-year risk of stroke in patients with perioperative atrial fibrillation after noncardiac surgery, and the safety and efficacy of valve-in-valve transcatheter aortic valve replacement for stentless bioprosthetic aortic valves.
The 100th episode of the View examines whether statistical adjustments in a new observational analysis of the Digitalis Investigation Group trial reveal the true treatment effect of digoxin and the association of mineralocorticoid receptor antagonist use with all-cause mortality and hospital readmission in patients with acute heart failure. This episode also offers a closer look at the various online learning tools available on ACC.org.
This week's View explores whether post-TAVR 30-day stroke risk has declined as device technology and operator experience have improved, what the optimum SBT duration and impact of pressure support ventilation are in relation to the likelihood of extubation success and other outcomes, and if a simple risk-assessment tool can be developed for patients undergoing preoperative evaluation before noncardiac surgery.
This week's View explores whether there is a genetic relationship of cardiovascular diseases (CVDs) and non-CVDs with reported coronary artery disease comorbidity and summarizes key points to remember from a comparison of US and European blood pressure guidelines and from a state-of-the-art review on renal denervation.
This week's View focuses on three trials investigating whether alirocumab reduces death after an index acute coronary syndrome, whether lisinopril or carvedilol is superior to placebo at preventing left ventricular systolic dysfunction, and whether icosapent ethyl safely reduces cardiovascular events among patients with high triglycerides.
This week's View explores the effect of arteriovenous fistula ligation on cardiac structure and function in stable kidney transplant recipients, the relationship between new-onset perioperative/postoperative atrial fibrillation and early and late stroke and mortality, and the risk of recurrent venous thromboembolism (VTE) following surgery in patients with a prior history of VTE.
This week's View explores the efficacy and safety outcomes for new-generation drug-eluting stents compared with bare-metal stents, the effects of beta-blockers and calcium antagonists on clinical outcomes in stable coronary artery disease, and a recent update on clinical trials of losartan with and without beta-blockers to block aneurysm growth in patients with Marfan syndrome.
This week's View covers articles about arrhythmia-induced cardiomyopathy, echocardiographic markers' ability to predict an abnormal diastolic response to exercise among dyspneic patients with mild left ventricular diastolic dysfunction, and the prognostic value of galectin-3 in patients with acute myocardial infarction.
This week's View addresses the differences in comorbidities and adverse pregnancy-related events and outcomes in women with congenital heart defects, key points to remember from a review on exercise intolerance in patients with heart failure, and whether lipoprotein (a) and oxidized phospholipids on apolipoprotein B-100 are associated with disease activity/progression and clinical events in patients with aortic stenosis.
This week's View examines the impact of a preschool-based health promotion educational intervention in an underserved community, explores the association between dietary patterns and incident heart failure among participants without known coronary artery disease, and outlines key points to remember from a document proposing a system of care for patients with valvular heart disease.
Part 2 of this week’s View features guest host Dr. Deepak Bhatt, who covers the contemporary diagnosis-specific outcomes in pregnant women with heart disease, key points to remember from the American Heart Association Scientific Statement on the diagnosis and management of myocardial infarction in the absence of obstructive coronary artery disease, and the relative efficacies of sirolimus-eluting versus everolimus-eluting stents for target lesion revascularization.
Part 1 of this week's View features guest host Dr. Deepak Bhatt, who explores the impact of chest compression-only cardiopulmonary resuscitation on survival among out-of-hospital cardiac arrest victims, the effect of endovascular thrombectomy cumulative case volume on outcomes of acute stroke patients, and the association between hospital or operator volume of transcatheter aortic valve replacement procedures and 30-day unadjusted and risk-adjusted outcomes.
This week's View covers an American Heart Association Scientific Statement about cardiorenal syndrome, a study that examines whether dietary consumption or egg consumption is associated with cardiovascular disease and all-cause mortality, and a study of the angiographic characteristics of the dissected segments in a large cohort of patients with spontaneous coronary artery dissection who had subsequent repeat coronary angiography.
In this special episode of Eagle’s Eye View, Dr. Peter Block, Dr. Kim Eagle, and Dr. Deepak Bhatt discuss highlights from Day 3 of ACC.19, including IRAD: Acute Aortic Dissection: Lessons Learned From 9000 Patients, REDUCE-IT: Reduction in Total Ischemic Events With Icosapent Ethyl, DECLARE-TIMI 58 HFrEF: Dapagliflozin on HF and Mortality in T2D Based on EF, and SAFARI-STEMI: Femoral Access vs. Radial Access For Primary PCI in STEMI.
In this special episode of Eagle’s Eye View, Dr. Peter Block, Dr. Kim Eagle, and Dr. Deepak Bhatt discuss highlights from Day 2 of ACC.19, including PARTNER 3: TAVR or SAVR in Low-Risk Patients, AUGUSTUS: Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in AFib and ACS, PCI, POET: Partial Oral Treatment of Left-Sided Infectious Endocarditis, and MOMENTUM 3: MagLev Technology in Mechanical Circulatory Support Therapy With HeartMate 3.
In this special episode of Eagle's Eye View, Dr. Peter Block and Dr. Deepak Bhatt discuss highlights from Day 1 of ACC.19, including the Apple Heart Study, PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated HF, Hopeful Heart: Blended Collaborative Care For Treating HF and Comorbid Depression, and CODIACS-QoL: Depression Screening After ACS.
This week's View includes key points to remember from a review article about postural orthostatic tachycardia syndrome, discussion of an analysis of the efficacy of direct oral anticoagulants in patients with mitral stenosis, and a summary of ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study): Blood Pressure Reduction.
In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at ACC.19, taking place March 16-18 in New Orleans, including the Apple Heart study, results of the open-label extension of the PIONEER-HF trial, the HoT-PE study, results of the PARTNER 3 trial, and Self-Expanding TAVR or SAVR in Patients at Low Risk of Surgical Mortality.
This week's View lists key points to remember about the American Heart Association 2019 update on the statistics regarding heart disease, stroke, and cardiovascular risk factors and discusses two clinical trials evaluating anticoagulants compared with placebo among patients with cancer and risk for venous thromboembolism.
This week's View focuses on heart disease in women, addressing the long-term risk of developing heart failure (HF) after trastuzumab therapy, how sex differences contribute to exercise intolerance in patients with HF with preserved ejection fraction, and gender differences in adverse drug reactions to HF medication.
This week's View explores the association between heart failure and risk of postoperative morbidity and mortality among patients undergoing noncardiac surgery and analyzes a study on the safety and efficacy of transdermal glyceryl trinitrate when given by paramedics very early after presumed stroke onset but before admission to the hospital, touching on key points to remember from an article on real-world treatment trends in endovascular stroke therapy.
This week's View offers key points to remember from a review on heart failure with preserved ejection fraction and diabetes and addresses the comparative durabilities of transcatheter aortic valve replacement (TAVR) and surgical bioprosthetic aortic valve replacement and the incidence of structural valve degeneration 5-10 years after TAVR.
This week's View offers key points to remember from a review about the use of cardiovascular medications during pregnancy, key points to remember from the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, and highlights from a subsequent analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial.
This week's View offers key points to remember from the 2018 Fourth Universal Definition of Myocardial Infarction Consensus Document and addresses the risk of rupture of abdominal aortic aneurysm in men under surveillance and the variation in revascularization of asymptomatic patients with stable ischemic heart disease.
This week's View explores whether a risk prediction model can predict life-years gained without myocardial infarction or stroke in people with type 2 diabetes mellitus, the effects of a loading dose of a statin before percutaneous coronary intervention (PCI) in patients with acute coronary syndrome, and the mechanisms and diagnosis of recurrent or persistent angina in patients after PCI.
This week's View explores whether the coronary artery calcium score identify persons most likely to have a reduction in atherosclerotic cardiovascular disease events with statin treatment and outlines optimal exercise programs for patients with peripheral artery disease.
This week's View offers a round-up of the most popular content on ACC.org in 2018, including guidelines, journal scans, key points, clinical trials, and Certified Patient Cases, as well as news from CardioSmart.
This week's View explores two trials on percutaneous mitral valve repair, MITRA-FR (Percutaneous Repair With the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation) and COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), and a review letter on elevation of cardiac troponins after endurance running competitions.
This week's View addresses the racial/ethnic differences in the use of oral anticoagulant therapy in patients with atrial fibrillation, the real-world data on efficacy and safety of catheter ablation for tachyarrhythmias, and the risk of major congenital malformations associated with use of beta-blockers during the first trimester.
In this special episode of the View, Kim Eagle and Peter Block discuss the highlights from Day 1 of the 2018 American Heart Association Scientific Sessions, including the VITAL, CIRT, and REDUCE-IT trials.
This week's View reviews important points and perspectives from the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay.
In this week's View, Dr. Deepak Bhatt gives us a preview of hot trials that will be presented November 10-12 at the 2018 American Heart Association Scientific Sessions in Chicago, IL.
This week's View explores initial two-drug pharmacotherapy for hypertension, antihypertensive therapy in adults with mild hypertension at low risk for cardiovascular disease, and transcatheter mitral valve replacement for patients with degenerated bioprostheses, failed annuloplasty rings, and severe mitral annular calcification.
This week's View summarizes three recent clinical trials: ASPREE (Aspirin in Reducing Events in the Elderly) and ASCEND Aspirin and ASCEND Omega-3 (A Study of Cardiovascular Events in Diabetes).
This week's View explores the outcomes of complete revascularization compared with culprit vessel-only intervention in patients undergoing percutaneous coronary intervention, the long-term prognostic value of grayscale and radiofrequency intravascular ultrasound-based plaque characteristics among patients with coronary artery disease undergoing angiography, and whether new-onset postoperative atrial fibrillation following noncardiac surgery is associated with stroke.
This week's View explores the addition of P-wave indices to improve the predictive ability of the CHA2DS2-VASc score for atrial fibrillation-related stroke risk, the effects of liraglutide on cardiovascular and safety outcomes in subgroups of patients with type 2 diabetes and chronic kidney disease, and whether percutaneous septal radiofrequency ablation can be effective treatment for patients with hypertrophic cardiomyopathy with obstruction.
This week's View delves into how evidence-based treatments of non-ST-segment elevation (NSTE) myocardial infarction affect short- and long-term outcomes, the modes of death following NSTE acute coronary syndromes in clinical trial populations, and key points from the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy.
This week's View touches on a study examining the association between diary consumption and risk for mortality and major cardiovascular events, a study evaluating low-dose aspirin compared with placebo among healthy elderly patients, and a study investigating whether the use of guideline-indicated treatments for non-ST-segment elevation myocardial infarction is associated with improved survival across the spectrum of risk.
This week's View focuses on key points to remember about the 2018 European Society of Cardiology/European Society of Hypertension Guidelines for the Management of Arterial Hypertension.
This week's View summarizes the ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) and GLOBAL LEADERS trials and an article about the variability of left ventricular (LV) ejection fraction measured by different imaging modalities in patients with LV dysfunction.
In this week's View, guest host Dr. Deepak Bhatt offers a preview of the hottest science at ESC Congress 2018, including updates from the CULPRIT-SHOCK, COMPASS, CABANA, and ART trials and late-breaking data from the MARINER, ARRIVE, ASCEND, COMMANDER-HF, and GLOBAL LEADERS trials.
This week's View reviews key points from the 2018 American Heart Association/American College of Cardiology Guideline for the Management of Adults With Congenital Heart Disease.
This week's View offers an analysis of screening programs for abdominal aortic aneurysm in women; a discussion of the relationship among obesity, coronary microvascular dysfunction, and adverse outcomes; and an update of the EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.
This week's View offers a summary of BRUISE CONTROL-2 (A Randomized Controlled Trial of Continued Versus Interrupted Direct Oral Anti-Coagulant at the Time of Device Surgery), key points from the updated recommendations on sports participation in athlete patients with coronary artery disease, and a discussion of the diagnostic performance of the European Society of Cardiology high-sensitivity cardiac troponin 0/1-hour algorithm in patients presenting to the emergency department with chest pain.
This week's View reviews recent articles about the clinical effects of aspirin therapy according to body weight and dose, the predictive accuracy of pooled cohort equations in a multiethnic cohort of women, and the validity/performance of prediction models for outcome after carotid revascularization.
This week’s View offers key points from an article about the mechanism, use, and future of proprotein convertase subtilisin/kexin type 9 inhibitors.